Evidence map›Paper›PMID 40628852›Full record

ArticleScientific reports2025

CRO-67 has anti-cancer activity in pancreatic tumor cells and stromal cancer-associated fibroblasts.

Shannon Chiang, Keilah Garcia Netto, John Kokkinos, Koroush S Haghighi, Aparna S Raina, Janet Youkhana, Omali Pitiyarachchi, Quach Truong, Daniel Wenholz, John Wilkinson and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Shannon Chiang *Pancreatic Cancer Translational Research Group, School of Biomedical Sciences, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW, 2052, Australia.
Keilah Garcia Netto *Pancreatic Cancer Translational Research Group, School of Biomedical Sciences, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW, 2052, Australia.
John Kokkinos *Pancreatic Cancer Translational Research Group, School of Biomedical Sciences, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW, 2052, Australia.
Koroush S HaghighiPrince of Wales Hospital, School of Clinical Medicine, Randwick Clinical Campus, UNSW Sydney, Sydney, NSW, 2052, Australia.
Aparna S RainaPancreatic Cancer Translational Research Group, School of Biomedical Sciences, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW, 2052, Australia.
Janet YoukhanaPancreatic Cancer Translational Research Group, School of Biomedical Sciences, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW, 2052, Australia.
Omali PitiyarachchiPancreatic Cancer Translational Research Group, School of Biomedical Sciences, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW, 2052, Australia.
Quach TruongNoxopharm Limited, Sydney, NSW, 2154, Australia.
Daniel WenholzNoxopharm Limited, Sydney, NSW, 2154, Australia.
John WilkinsonNoxopharm Limited, Sydney, NSW, 2154, Australia.
Olivier LaczkaNoxopharm Limited, Sydney, NSW, 2154, Australia.
Xiang LiNoxopharm Limited, Sydney, NSW, 2154, Australia.
Vina R AldillaSchool of Chemistry, UNSW Sydney, Sydney, NSW, 2052, Australia.
Naresh KumarSchool of Chemistry, UNSW Sydney, Sydney, NSW, 2052, Australia.
David GoldsteinPancreatic Cancer Translational Research Group, School of Biomedical Sciences, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW, 2052, Australia.
George SharbeenPancreatic Cancer Translational Research Group, School of Biomedical Sciences, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW, 2052, Australia. g.sharbeen@unsw.edu.au.
Phoebe A PhillipsPancreatic Cancer Translational Research Group, School of Biomedical Sciences, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW, 2052, Australia. p.phillips@unsw.edu.au.

Funding

Cancer Institute NSW Translational Program Grant 2020/TPG2100NHMRC Ideas Grant APP2002707SPHERE/Cancer Institute NSW Translational Cancer Research Capacity Building Grant 2021/CBG0003
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy that urgently needs more effective therapies. Cancer-associated fibroblasts (CAFs) contribute to the aggressive and chemo-resistant nature of the disease by creating a drug-impeding fibrotic microenvironment. We developed novel compounds, the racemate CRO-05 and its active enantiomer CRO-67, which target both pancreatic tumor and CAF cells with robust anti-cancer activity. These compounds were designed using rational medicinal chemistry based on chromans, a class of anti-cancer drugs. Their therapeutic potential and efficacy were assessed in a clinically relevant patient-derived PDAC tumor explant model, which mimics the disease's 3-dimensional complexity. CRO-67 treatment in these explants significantly reduced tumor cell and αSMA

Indexed as

Antineoplastic AgentsCancer-Associated FibroblastsCarcinoma, Pancreatic DuctalPancreatic NeoplasmsAnimalsApoptosisCell Line, TumorCell ProliferationHumansMiceTumor MicroenvironmentXenograft Model Antitumor AssaysAntineoplastic AgentsCancer-associated fibroblastCRO-67Pancreatic cancerStromal reprogramming

Identifiers

PMID40628852
PMCPMC12238265

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.